DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
MWN-AI** Summary
DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), based in Brossard, Quebec, has made significant strides in cybersecurity certification for its CARA System application, aimed at enhancing the early detection of ophthalmic health issues through artificial intelligence (AI). The company recently announced successful completion of extensive penetration testing aligned with the cybersecurity requirements set by the Quebec Ministry of Health, as part of its progression towards ISO 27001 certification.
Following the identification of vulnerabilities during these tests, DIAGNOS acted swiftly to address and rectify the issues, reaffirmed through thorough regression testing. This proactive approach resulted in a favorable assessment of CARA's security performance from the Cyber Defense Operations Center (COCD), demonstrating compliance with rigorous cybersecurity protocols.
With this certification, DIAGNOS has communicated to Quebec's healthcare institutions, including CISSS, CIUSSS, and CHUM, that they are authorized to incorporate the CARA System into their ongoing projects. DIAGNOS CEO André Larente underscored the company’s dedication to protecting personal data and reassured users regarding the robust security measures in place for the CARA application. Larente emphasized that this successful assessment marks a crucial milestone in their effort to obtain the ISO 27001 certification, with scheduled audits by certification body Intertek on the horizon.
As DIAGNOS continues to advance in its certification process, an update is anticipated this summer. The company, committed to improving diagnostic accuracy and patient outcomes globally through AI technologies, continues to strengthen its cybersecurity framework, ensuring that personal data protection remains a top priority. For more information, visit www.diagnos.com.
MWN-AI** Analysis
DIAGNOS's recent announcement regarding major advancements in cybersecurity certification for its CARA System application positions the company as a key player in the healthcare technology sector. By successfully navigating stringent penetration tests mandated by Quebec's Ministry of Health and securing a positive assessment from the Cyber Defense Operations Center (COCD), DIAGNOS has underscored its commitment to data protection—a critical factor in gaining traction with healthcare institutions.
Investors should view this development favorably, as enhanced cybersecurity measures can lead to increased adoption of DIAGNOS's services among healthcare providers who are increasingly concerned about compliance and patient data privacy. The proactive approach in correcting vulnerabilities and moving towards ISO 27001 certification serves to bolster investor confidence. It also positions DIAGNOS as a responsible tech vendor amid a landscape where cybersecurity is paramount.
Furthermore, the collaboration with Quebec's healthcare institutions, including CISSS and CIUSSS, signals a robust market strategy aimed at gaining a significant foothold in a crucial industry sector. This endorsement can act as a catalyst for future contracts, which may drive revenue growth.
However, potential investors should remain cautious. Given the forward-looking nature of the announcement, it is essential to monitor the upcoming audit results regarding ISO 27001 certification. Additionally, while DIAGNOS is on a promising trajectory, the broader market and regulatory environment will play a crucial role in shaping its near-term performance.
Overall, DIAGNOS demonstrates a forward-thinking approach and commitment to cybersecurity, which should resonate well within the healthcare community and offer potential growth opportunities for investors looking to enter the tech-enabled healthcare sector. Holding shares could be a strategic decision as the company continues to execute its plans effectively.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence ( AI ), announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application.
As part of its ongoing ISO 27001 certification process, DIAGNOS is pleased to announce that its CARA System application has recently undergone a series of extensive penetration tests, in accordance with the cybersecurity requirements of the Quebec Ministry of Health. The vulnerabilities identified during these tests were rapidly corrected following regression tests carried out in early March 2025. These measures enabled DIAGNOS to receive a positive assessment of CARA's security posture from the Cyber Defense Operational Center (COCD), underlining compliance with stringent cybersecurity standards.
An official notification has been sent to Quebec's healthcare institutions, including CISSS and CIUSSS, as well as CHUM, authorizing them to integrate CARA into their projects.
“Protecting personal data is at the heart of our commitment to our customers. The successful completion of our intrusion test validated by Quebec's Centre opérationnel de cybersécurité gouvernemental (COCD) is indisputable proof of the high level of security of our CARA application. This test marks a key step in our drive to obtain ISO 27001 certification. The planned verification audit will be decisive in confirming our ongoing efforts and commitment to the highest standards of cybersecurity. Our users can have total confidence in our rigorous standards to protect their information. André Larente, CEO DIAGNOS ”
In addition, DIAGNOS is also proud to announce that its ISO 27001 certification process is progressing according to plan. Audit dates with certification body Intertek have been set, and an update will be published over the summer.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com .
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.ca
FAQ**
How does the cybersecurity certification from the Cyber Defense Operations Center (COCD) enhance the market competitiveness of Diagnos Inc. ADK:CC in the healthcare technology sector?
What specific benefits will Quebec's healthcare institutions gain by integrating Diagnos Inc. ADK:CC's CARA System into their projects following the positive security assessment?
Can you provide more details on the planned verification audit for ISO 27001 certification and how it will impact the future operations of Diagnos Inc. ADK:CC?
In what ways does the successful completion of penetration tests demonstrate Diagnos Inc. ADK:CC's commitment to protecting personal data and ensuring patient confidentiality?
**MWN-AI FAQ is based on asking OpenAI questions about Diagnos Inc. (TSXVC: ADK:CC).
NASDAQ: ADK:CC
ADK:CC Trading
0.0% G/L:
$0.22 Last:
18,502 Volume:
$0.22 Open:
